Exchange Traded Concepts LLC Has $774,000 Stock Position in Prestige Consumer Healthcare Inc. $PBH

Exchange Traded Concepts LLC reduced its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 43.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,410 shares of the company’s stock after selling 9,527 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Prestige Consumer Healthcare were worth $774,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UMB Bank n.a. increased its stake in shares of Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock valued at $26,000 after acquiring an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares in the last quarter. Maseco LLP acquired a new position in shares of Prestige Consumer Healthcare during the second quarter valued at about $27,000. Geneos Wealth Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $46,000. 99.95% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price on the stock in a research report on Wednesday, September 24th. Oppenheimer reduced their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Jefferies Financial Group decreased their price target on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research note on Monday, October 27th. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.33.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the transaction, the vice president owned 42,329 shares in the company, valued at $2,539,740. The trade was a 1.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.40% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Trading Up 1.3%

NYSE PBH opened at $63.67 on Tuesday. The company has a current ratio of 3.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55. The business has a fifty day simple moving average of $60.82 and a 200 day simple moving average of $67.00. Prestige Consumer Healthcare Inc. has a 12 month low of $57.25 and a 12 month high of $90.04. The firm has a market capitalization of $3.06 billion, a P/E ratio of 15.80, a PEG ratio of 1.97 and a beta of 0.39.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm had revenue of $274.11 million for the quarter, compared to the consensus estimate of $257.14 million. During the same period in the previous year, the firm earned $1.09 EPS. The business’s revenue for the quarter was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).